As our sample size is small to draw concrete conclusion at this point, it will be interesting to explore whether overexpression of hepatic PRMT1 can also protect against NAFLD-induced liver injury in other large cohort studies. The gene discussed is PRMT1; the disease is metabolic dysfunction-associated steatotic liver disease.